SPT-348

SPT-348 is a serotonin receptor modulator and non-hallucinogenic psychoplastogen of the lysergamide family which is under development for the treatment of depression, anxiety, and other neuropsychiatric disorders.^[1][2][3][4] It is a prodrug of 2-bromo-LSD (bromolysergide; BOL-148), a non-selective serotonin receptor modulator and partial agonist of the serotonin 5-HT_2A receptor,^[5][6] and is an analogue of the serotonergic psychedelic LSD.^[3][4] The drug is said to employ a novel formulation involving a triglyceride linker that helps it to bypass first-pass metabolism in the liver that is said to be prominent with LSD.^[2] As of 2025, SPT-348 is in the discovery or preclinical research stage of development.^[2][1]

SPT-348

Clinical data
Other names	SPT348
Drug class	Non-hallucinogenic psychoplastogen; Non-selective serotonin receptor modulator; Non-hallucinogenic serotonin 5-HT2A receptor partial agonist
ATC code	None

See also

• List of investigational hallucinogens and entactogens
• JRT
• Lisuride